Transcripts identifiedin Her2-NLP-treated groups relative to either untreated or empty-NLP-treatedfactors overlapped with previously reported screens for acinar morphogenesis(EBI3, CCL5)32 and for residual diseasein Her2+ breast cancer (CCL533,34), breast cancer outcome(EBI335−37), and metastasis (TGM2,38 EBI337,39). This evidence concerns the gene ERBB2 and breast cancer.